Navigation Links
Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy

TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 1, 2007 - Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced positive results from the first clinical trial of its investigational drug, PRO 140, in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. Patients receiving a single 5.0 mg/kg dose of PRO 140 achieved an average maximum decrease of viral concentrations in the blood of 98.5% (1.83 log10), with individual reductions ranging up to 99.7% (2.5 log10). In these patients, reductions in viral load of greater than 90% (1.0 log10) on average persisted for two to three weeks after dosing. In addition, PRO 140 was generally well tolerated in this phase 1b proof-of-concept study. PRO 140 was granted Fast Track status from the U.S. Food and Drug Administration (FDA), and Progenics plans to initiate additional clinical testing in the second half of 2007.

"This study establishes clear proof of concept for PRO 140 as a potent antiretroviral agent with extended activity following a single dose," said Scott M. Hammer, M.D., Chief, Division of Infectious Diseases and Harold C. Neu Professor of Medicine, Columbia University College of Physicians and Surgeons, New York City. "The primary goal of HIV therapy is to provide maximal and durable suppression of viral replication. Based on this study, PRO 140 has the potential to add to the armamentarium of drugs that can help achieve this goal in patients living with HIV, including those whose treatment options are limited by drug resistance."

PRO 140 is a humanized monoclonal antibody that binds CCR5, the principal portal used by HIV to enter cells. Viral-entry inhibition using a long-lived antibody represents a promising novel approach to treating HIV infection. Unlike currently available antiretroviral drugs, PRO 140 does not target the virus, but rather binds to the CCR5 receptor on healthy immune system cells and thereby pr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/29/2015)... MEMPHIS, Tenn. , May 29, 2015  Dr. ... his practice to resolve vaginal health issues often caused by ... painless and requires no anesthesia, received FDA clearance in 2014. ... Tennessee to offer the special fractional CO ... well as breast cancer survivors. In 2010 ...
(Date:5/29/2015)... LifeNet Health plans to enlarge its workforce ... more than 160 people. The organization,s growth ... innovative bio-implants, which are being made more widely available ... It also is a reflection of the region,s growing ... and success of LifeNet Health is a great example ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... American Association of Cancer Research (AACR) Advances ... potential for its lead product candidate VAL-083 ...
Breaking Medicine Technology:The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2LifeNet Health to add more than 160 jobs in 2015 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... AAHC Calls for National Entity to Address Workforce ... center CEOs told congressional staff and representatives of ... that pending health reform legislation does not yet ... to implement successful health system reform. "Pending ...
... AMN Healthcare Services, Inc. (NYSE: AHS ), the ... its quarterly conference call to discuss third quarter results on ... company also expects to issue an earnings news release on ... approximately 4:00 p.m. Eastern Time. , A live webcast of ...
Cached Medicine Technology:Health Reform Bills Still Lack Strategic Focus on Health Workforce 2AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2
(Date:5/29/2015)... May 29, 2015 Intermountain ... partnered with Stratus Video Interpreting ... facilitate better communication and timely care for ... hearing loss. Stratus’ video remote interpreting (VRI) ... enabling staff to quickly access qualified medical ...
(Date:5/29/2015)... 29, 2015 Mediaplanet has joined forces ... readers on the importance of proper sun protection. The ... Today, with a circulation of approximately 250,000 copies and ... is distributed nationally, through a vast social media strategy, ... partner outlets. To explore the digital version of the ...
(Date:5/29/2015)... Chicago, Ill (PRWEB) May 29, 2015 ... Care , a dozen medical pioneers recognized by a ... changed the course of cancer treatment. Honorees will be ... of Cancer Care™ Award Ceremony, held 8:30-11:00 p.m. CDT ... , The 2015 honorees are being recognized for groundbreaking ...
(Date:5/29/2015)... TX (PRWEB) May 29, 2015 ... 2015” provides comprehensive information on the therapeutic development ... types of muscles in the body, leading to ... R&D pipelines by identifying new targets and MOAs ... on H1 2015 pipeline review of Axillary Hyperhidrosis ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of ... is now offering free weekly call in teleconferences ... ways to reduce symptoms associated with fibromyalgia including ... brain fog. , To find out more ... call in teleconferences simply go to http://www.endfibronow.com ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... PA, January 3, 2011 Postoperative adhesions are a ... used in the hopes of preventing these adhesions by ... in the December 2010 issue of the Journal ... Association of Pediatric Ophthalmology and Strabismus, a team of ...
... entered into a collaborative agreement with Veridex LLC to ... tumor cell (CTC) technologies. The overall goal of the ... capturing and characterizing CTCs, solid tumor cells found at ... a key to noninvasive characterization of cancer and potentially ...
... , SUNDAY, Jan. 2 (HealthDay News) -- Snowblowers ... the white stuff, but while these machines may leave your ... bandage -- or worse, experts warn. A hand surgeon ... accidents can severely injure hands and even require finger amputations ...
... , THURSDAY, Dec. 30 (HealthDay News) -- Certain ... a new study finds. Because of increasing urbanization, ... more than ever before. For example, foxes, raccoons and ... mice, rats, birds and other prey. For this ...
... , , , , , , ... , , AUDIO: ... , Click here for more information. , ... , , , , ...
... THURSDAY, Dec. 29 (HealthDay News) -- Following mothers, advice may ... crisis. Fears of the H1N1 flu virus reached a ... widespread outbreak caused by short supplies of the needed vaccine. ... that,s because more people than ever before regularly washed their ...
Cached Medicine News:Health News:Use of amniotic membrane may cause complications in strabismus surgery 2Health News:Mass. General enters collaboration to develop new approach to capturing circulating tumor cells 2Health News:Risk for alcoholism linked to risk for obesity 2Health News:Risk for alcoholism linked to risk for obesity 3Health News:Risk for alcoholism linked to risk for obesity 4Health News:Hand-Washing May Have Kept Flu at Bay 2Health News:Hand-Washing May Have Kept Flu at Bay 3
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... The SURPASS Perfusion Catheter is ... the stenotic portion of a ... stenosis for the purpose of ... Perfusion Catheters are also designed ...
Medicine Products: